Central Activation and Force-Frequency Responses of the Lumbar Extensor Muscles

Russ, David W.; Ruggeri, Rachel G.; Thomas, James S.

doi:10.1249/mss.0b013e31819b3607

Cited by 3 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The underlying cause of this phenomenon remains to be elucidated. It is unlikely that it is due to any decreased sensitivity of myofilaments to calcium, because we found that the stimulation frequency for which 50% of the maximum force was exerted—an in vivo indicator of calcium sensitivity (57)—was not affected by sActRIIB‐Fc treatment. On the other hand, it has been established that myostatin deficiency reduces muscle collagen content, thereby altering muscle mechanistic by increasing the stiffness of muscle aponeurosis and tendon (58, 59).…”

Section: Discussionmentioning

confidence: 89%

ActRIIB blockade increases force‐generating capacity and preserves energy supply in exercisingmdxmouse musclein vivo

et al. 2016

View full text Add to dashboard Cite

Postnatal blockade of the activin type IIB receptor (ActRIIB) represents a promising therapeutic strategy for counteracting dystrophic muscle wasting. However, its impact on muscle function and bioenergetics remains poorly documented in physiologic conditions. We have investigated totally noninvasively the effect of 8-wk administration of either soluble ActRIIB signaling inhibitor (sActRIIB-Fc) or vehicle PBS (control) on gastrocnemius muscle force-generating capacity, energy metabolism, and anatomy in dystrophic mdx mice using magnetic resonance (MR) imaging and dynamic [P]-MR spectroscopy ([P]-MRS) in vivo ActRIIB inhibition increased muscle volume (+33%) without changing fiber-type distribution, and increased basal animal oxygen consumption (+22%) and energy expenditure (+23%). During an in vivo standardized fatiguing exercise, maximum and total absolute contractile forces were larger (+40 and 24%, respectively) in sActRIIB-Fc treated animals, whereas specific force-generating capacity and fatigue resistance remained unaffected. Furthermore, sActRIIB-Fc administration did not alter metabolic fluxes, ATP homeostasis, or contractile efficiency during the fatiguing bout of exercise, although it dramatically reduced the intrinsic mitochondrial capacity for producing ATP. Overall, sActRIIB-Fc treatment increased muscle mass and strength without altering the fundamental weakness characteristic of dystrophic mdx muscle. These data support the clinical interest of ActRIIB blockade for reversing dystrophic muscle wasting.-Béchir, N., Pecchi, E., Vilmen, C., Le Fur, Y., Amthor, H., Bernard, M., Bendahan, D., Giannesini, B. ActRIIB blockade increases force-generating capacity and preserves energy supply in exercising mdx mouse muscle in vivo.

show abstract

Section: Discussionmentioning

confidence: 89%

ActRIIB blockade increases force‐generating capacity and preserves energy supply in exercisingmdxmouse musclein vivo

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Accumulation of tubular aggregates at the calcium release channel of the sarcoplasmic reticulum has also been proposed to alter calcium handling during excitation-contraction cycles in myostatin-deficient mice, thereby altering mechanical performance (2,9). Nevertheless, this issue remains unlikely herein, because we found that ActRIIB blockade did not affect f 50 (the electrostimulation frequency for which 50% of the maximal tetanic force was exerted), an in vivo indicator of calcium sensitivity (21,54). On the other hand, it is possible that the reduced mechanical capacity in sActRIIB-Fc-treated animals was linked to hypertrophy-induced alterations of fiber pennation angles caused by increased muscle cross-sectional area.…”

Section: Discussionmentioning

confidence: 71%

Mitochondrial impairment induced by postnatal ActRIIB blockade does not alter function and energy status in exercising mouse glycolytic muscle in vivo

Béchir

Pecchi

Relizani

et al. 2016

American Journal of Physiology-Endocrinology and Metabolism

View full text Add to dashboard Cite

-Because it leads to a rapid and massive muscle hypertrophy, postnatal blockade of the activin type IIB receptor (ActRIIB) is a promising therapeutic strategy for counteracting muscle wasting. However, the functional consequences remain very poorly documented in vivo. Here, we have investigated the impact of 8-wk ActRIIB blockade with soluble receptor (sActRIIB-Fc) on gastrocnemius muscle anatomy, energy metabolism, and force-generating capacity in wild-type mice, using totally noninvasive magnetic resonance imaging (MRI) and dynamic 31 P-MRS. Compared with vehicle (PBS) control, sActRIIB-Fc treatment resulted in a dramatic increase in body weight (ϩ29%) and muscle volume (ϩ58%) calculated from hindlimb MR imaging, but did not alter fiber type distribution determined via myosin heavy chain isoform analysis. In resting muscle, sActRIIB-Fc treatment induced acidosis and PCr depletion, thereby suggesting reduced tissue oxygenation. During an in vivo fatiguing exercise (6-min repeated maximal isometric contraction electrically induced at 1.7 Hz), maximal and total absolute forces were larger in sActRIIB-Fc treated animals (ϩ26 and ϩ12%, respectively), whereas specific force and fatigue resistance were lower (Ϫ30 and Ϫ37%, respectively). Treatment with sActRIIB-Fc further decreased the maximal rate of oxidative ATP synthesis (Ϫ42%) and the oxidative capacity (Ϫ34%), but did not alter the bioenergetics status in contracting muscle. Our findings demonstrate in vivo that sActRIIB-Fc treatment increases absolute force-generating capacity and reduces mitochondrial function in glycolytic gastrocnemius muscle, but this reduction does not compromise energy status during sustained activity. Overall, these data support the clinical interest of postnatal ActRIIB blockade. skeletal muscle hypertrophy; activin type IIB receptor; myostatin; force; fatigue ACTIVIN TYPE IIB RECEPTOR (ActRIIB) is a transmembrane serinethreonine kinase receptor highly expressed in mammalian skeletal muscle. It mediates signaling for myostatin (GDF8) and other members of the transforming growth factor-␤ family that are involved in the negative regulation of skeletal muscle development (16,37). Disruption of the ActRIIB signaling pathway leads to a rapid and massive increase in muscle mass resulting from fiber hypertrophy with increased myofiber protein synthesis (10, 58). In that context, several pharmacological approaches based on the postnatal ActRIIB signaling blockade have been considered for counteracting muscle wasting commonly associated to aging, neuromuscular disorders and various catabolic diseases (17,33,38). These approaches mainly include the systemic delivery of neutralizing antibodies against ActRIIB or myostatin (31, 36), and injection of a soluble recombinant form of ActRIIB (sActRIIB-Fc), which acts as a decoy receptor disrupting the interaction of endogenous ActRIIB receptor with its ligands (5,38,44).Although ActRIIB signaling blockade has been already tested in patients (30, 57) and animal models (10,44,47) suffering from dystrophi...

show abstract

Muskelmechanik und Muskelaktionen

Seiberl¹,

Paternoster²

2022

Sportwissenschaft

View full text Add to dashboard Cite

Central Activation and Force-Frequency Responses of the Lumbar Extensor Muscles

Abstract: Central activation and force-frequency testing of the lumbar extensor muscles is feasible, and the data reported here represent, to our knowledge, the first of their kind in this muscle group.

Cited by 3 publications

References 32 publications

ActRIIB blockade increases force‐generating capacity and preserves energy supply in exercisingmdxmouse musclein vivo

ActRIIB blockade increases force‐generating capacity and preserves energy supply in exercisingmdxmouse musclein vivo

Mitochondrial impairment induced by postnatal ActRIIB blockade does not alter function and energy status in exercising mouse glycolytic muscle in vivo

Muskelmechanik und Muskelaktionen

Contact Info

Product

Resources

About